Nearly Nine Years In The Making, AstraZeneca Finally Unveils New Cambridge R&D Hub
Investment In New R&D Technologies
After an expensive and protracted construction, AstraZeneca hopes its Cambridge research center will help foster collaboration and extend its run of R&D success.
You may also be interested in...
AstraZeneca and Moderna’s mRNA-based candidate AZD8601 has shown promise in a small Phase II heart study, strengthening the latter’s foray into the cardiovascular arena and beyond its vaccine niche.
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.